Next Article in Journal
Differential Urinary Proteomic Analysis of High-Risk Cervical Intraepithelial Neoplasia
Next Article in Special Issue
Role of the Water–Metal Ion Bridge in Quinolone Interactions with Escherichia coli Gyrase
Previous Article in Journal
Microbiota-Associated HAF-EVs Regulate Monocytes by Triggering or Inhibiting Inflammasome Activation
Previous Article in Special Issue
A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with Staphylococcus aureus DNA Gyrase
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents

by
Cosmas O. Okoro
* and
Toluwase Hezekiah Fatoki
Department of Chemistry, Tennessee State University, Boswell Science Complex, Nashville, TN 37209-1561, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(3), 2532; https://doi.org/10.3390/ijms24032532
Submission received: 2 November 2022 / Revised: 15 January 2023 / Accepted: 16 January 2023 / Published: 28 January 2023

Abstract

Several reviews of inhibitors of topoisomerase II have been published, covering research before 2018. Therefore, this review is focused primarily on more recent publications with relevant points from the earlier literature. Topoisomerase II is an established target for anticancer drugs, which are further subdivided into poisons and catalytic inhibitors. While most of the topoisomerase II-based drugs in clinical use are mostly topoisomerase II poisons, their mechanism of action has posed severe concern due to DNA damaging potential, including the development of multi-drug resistance. As a result, we are beginning to see a gradual paradigm shift towards non-DNA damaging agents, such as the lesser studied topoisomerase II catalytic inhibitors. In addition, this review describes some novel selective catalytic topoisomerase II inhibitors. The ultimate goal is to bring researchers up to speed by curating and delineating new scaffolds as the leads for the optimization and development of new potent, safe, and selective agents for the treatment of cancer.
Keywords: mini; topoisomerase II; catalytic inhibitors; poisons; DNA; salicylate; cardiotoxicity; MD simulation mini; topoisomerase II; catalytic inhibitors; poisons; DNA; salicylate; cardiotoxicity; MD simulation

Share and Cite

MDPI and ACS Style

Okoro, C.O.; Fatoki, T.H. A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents. Int. J. Mol. Sci. 2023, 24, 2532. https://doi.org/10.3390/ijms24032532

AMA Style

Okoro CO, Fatoki TH. A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents. International Journal of Molecular Sciences. 2023; 24(3):2532. https://doi.org/10.3390/ijms24032532

Chicago/Turabian Style

Okoro, Cosmas O., and Toluwase Hezekiah Fatoki. 2023. "A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents" International Journal of Molecular Sciences 24, no. 3: 2532. https://doi.org/10.3390/ijms24032532

APA Style

Okoro, C. O., & Fatoki, T. H. (2023). A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents. International Journal of Molecular Sciences, 24(3), 2532. https://doi.org/10.3390/ijms24032532

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop